Part 1/8:
The Hepatitis C Landscape and Gilead Sciences: An Overview
The ongoing challenges in the hepatitis C landscape make for compelling discussions in the biotech industry. One company that continues to capture attention is Gilead Sciences, which stands out as a leader in the field. With sales exceeding $30 billion, Gilead is not just another biotech firm; it represents a significant portion of the healthcare landscape.